Geron Corp (GERN) Stock Price

GERNStock

$1.55+4.11%52W

Market Cap$995.83M

P/E—

PEG Ratio—

Div yield—

Beta0.59

GERN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-32.90%

Price vs S&P 500 (4W)1.78%

VGM Score55.30

Book Value / Share (Quarterly)$0.34

P/TBV (Annual)3.34x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)574.21%

Cash Flow / Share (Quarterly)$-0.18

Price vs S&P 500 (YTD)3.19%

Gross Margin (TTM)96.60%

Net Profit Margin (TTM)-33.05%

EPS (TTM)$-0.10

10-Day Avg Trading Volume8.39M

EPS Excl Extra (TTM)$-0.10

Revenue Growth (5Y)274.39%

EPS (Annual)$-0.13

ROI (Annual)-17.58%

Gross Margin (Annual)97.42%

Net Profit Margin (5Y Avg)-21993.22%

Cash / Share (Quarterly)$0.47

Revenue Growth QoQ (YoY)17.22%

ROA (Last FY)-14.64%

Revenue Growth TTM (YoY)24.39%

EBITD / Share (TTM)$-0.08

ROE (5Y Avg)-88.55%

Operating Margin (TTM)-25.31%

Cash Flow / Share (Annual)$-0.17

P/B Ratio4.60x

P/B Ratio (Quarterly)3.76x

Net Income / Employee (Annual)$-323,600

EV / Revenue (TTM)5.83x

Net Interest Coverage (TTM)-4.74x

ROA (TTM)-12.34%

EV / EBITDA (TTM)2537.41x

EPS Incl Extra (Annual)$-0.13

Current Ratio (Annual)4.66x

Quick Ratio (Quarterly)5.07x

3-Month Avg Trading Volume12.63M

52-Week Price Return4.11%

Revenue / Employee (TTM)$792,900

Tangible BV / Share (Quarterly)$2.47

P/S Ratio (Annual)5.47x

Asset Turnover (Annual)0.32x

52-Week High$2.01

Operating Margin (5Y Avg)-22678.24%

EPS Excl Extra (Annual)$-0.13

CapEx CAGR (5Y)-34.29%

Tangible BV CAGR (5Y)27.31%

26-Week Price Return-21.65%

Quick Ratio (Annual)3.58x

13-Week Price Return20.63%

Total Debt / Equity (Annual)1.10x

Current Ratio (Quarterly)6.92x

Enterprise Value$1.19B

Revenue / Share Growth (5Y)214.25%

Asset Turnover (TTM)0.37x

Book Value / Share Growth (5Y)-12.26%

Revenue / Employee (Annual)$712,700

Pretax Margin (Annual)-45.41%

Cash / Share (Annual)$0.56

3-Month Return Std Dev67.51%

Net Income / Employee (TTM)$-262,100

ROE (Last FY)-36.97%

Net Interest Coverage (Annual)-3.35x

EPS Basic Excl Extra (Annual)$-0.13

P/FCF (TTM)35.45x

Receivables Turnover (TTM)4.64x

Total Debt / Equity (Quarterly)1.14x

EPS Incl Extra (TTM)$-0.10

Receivables Turnover (Annual)0.24x

ROI (TTM)-14.09%

P/S Ratio (TTM)4.92x

Pretax Margin (5Y Avg)-21993.22%

Revenue / Share (Annual)$0.28

Tangible BV / Share (Annual)$2.47

Forward P/E36.31x

Price vs S&P 500 (52W)-14.20%

Year-to-Date Return15.15%

5-Day Price Return-0.65%

EPS Normalized (Annual)$-0.13

ROA (5Y Avg)-43.32%

Net Profit Margin (Annual)-45.41%

Month-to-Date Return17.83%

Cash Flow / Share (TTM)$-0.34

EBITD / Share (Annual)$-0.10

Operating Margin (Annual)-37.30%

LT Debt / Equity (Annual)1.03x

ROI (5Y Avg)-56.16%

LT Debt / Equity (Quarterly)1.05x

EPS Basic Excl Extra (TTM)$-0.10

P/TBV (Quarterly)3.34x

P/B Ratio (Annual)3.73x

Inventory Turnover (TTM)0.07x

Pretax Margin (TTM)-33.05%

Book Value / Share (Annual)$0.35

Price vs S&P 500 (13W)17.84%

Beta0.59x

P/FCF (Annual)109.05x

Revenue / Share (TTM)$0.30

ROE (TTM)-29.32%

52-Week Low$1.04

vGradeD

gGradeB

mGradeC

vgmGradeC

GERN Earnings Surprise History

Q2 25-0.02est. -0.03

Q3 25-0.03est. -0.04

Q4 25-0.02est. -0.04

Q1 26-0.00est. -0.02

Q2 26-0.02est. -0.01

GERN Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.92

4.00

4.18

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
GERNGeron Corp	D	B	C	$1.55
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Geron Corp

Geron is a biopharmaceutical company focused on telomerase inhibitors for blood cancers. Its lead product, RYTELO (imetelstat), is approved in the United States and European Union for transfusion-dependent lower-risk myelodysplastic syndromes. The company is conducting Phase 3 testing in myelofibrosis and advancing studies in other hematologic malignancies.